$ZYME

Schayowitz Adam (EVP, Head of R&D) sold 13,832 shares of Zymeworks Inc. (ZYME) at $25.85 ($0.36M total) on 2026-10-09.

Citizens maintained a Market Outperform rating and $32 price target for Zymeworks (ZYME). The stock trades at $27.12 with a $1.92B market cap, up 57% in a year. Analysts have a Strong Buy consensus, with targets ranging from $32 to $60. Zymeworks completed its acquisition of Theravance Biopharma, which could bring over $100M in annual royalties. The company has $572.5M in cash and is conducting a share buyback program. Recent FDA approvals and clinical developments also support its pipeline.

Zymeworks Inc. [ZYME] announced an acquisition that provides recurring cash flows and royalty streams, transitioning from milestone-based to stable revenue. The deal is non-dilutive and offers R&D and leadership synergies, with potential tax benefits.

Zymeworks (ZYME) completed its acquisition of Theravance Biopharma, adding the respiratory drug YUPELRI to its portfolio. The move aims to provide steady revenue and support growth. Zymeworks trades at a high P/S ratio of 53.9, reflecting growth expectations, but remains unprofitable. Its GF Score is 61, indicating moderate fundamental health with strengths in valuation and momentum but weaknesses in profitability and growth.

B. Riley analyst Mayank Mamtani highlighted top biotech picks ahead of 3Q26 earnings, including Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Eton Pharmaceuticals (ETON), Harrow (HROW), TG Therapeutics (TGTX), and Zymeworks (ZYME). The analyst provided price targets and revenue projections for each, noting macroeconomic challenges for small and mid-cap biotech stocks.

Zymeworks Inc. (ZYME) completed its acquisition of Theravance Biopharma, integrating the company to diversify its revenue streams. Zymeworks will host a conference call on September 28 to discuss the transaction details. The acquisition aims to advance Zymeworks' strategy of combining innovative R&D with commercial and royalty-based cash flows.

Zymeworks Inc. (ZYME) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Zymeworks Completes Acquisition of Theravance Biopharma • Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) Vancouver, British Columbia (September 23, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portf

Zymeworks (ZYME) shares fell after management announced a shift to a hybrid royalty and acquisition strategy, raising concerns about execution risk and earnings timing. Despite optimism around its FDA-approved drug Ziihera, investors worry about near-term volatility. The company also announced a $125 million share repurchase program and a pending Theravance Biopharma deal, but these moves did not alleviate concerns. Long-term, Zymeworks' antibody platforms and cash position could support multipl

Analysts maintained Buy ratings on Zymeworks (ZYME), Axsome Therapeutics (AXSM), and Ocugen (OCGN). ZYME's PT is $38 (Citi) and $40.20 (consensus). AXSM's PT is $256 (Wells Fargo) and $291 (consensus). OCGN's PT is $12 (Noble Financial) and $10.13 (consensus). All have Strong Buy consensus.

Zymeworks (ZYME) presented at the Wells Fargo Healthcare Conference, highlighting its strategy focused on zanidatamab, royalty income, and acquisitions. Zanidatamab received FDA approval for gastric cancer, with Jazz Pharmaceuticals raising its peak sales estimate to $3B-$5B. Zymeworks raised $600M in debt, repurchased 10.5M shares, and plans to acquire Theravance Respiratory. Management expects profitability in 2026, with analysts forecasting 34% upside.